Genvoya
Drug
Gilead Sciences Inc
Total Payments
$10.8M
Transactions
4,614
Doctors
675
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $264,034 | 6 | 0 |
| 2022 | $306,117 | 18 | 0 |
| 2021 | $393,803 | 24 | 0 |
| 2020 | $1.1M | 52 | 0 |
| 2019 | $3.3M | 141 | 1 |
| 2018 | $1.4M | 269 | 22 |
| 2017 | $4.0M | 4,104 | 666 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.9M | 1,426 | 82.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 612 | 12.9% |
| Travel and Lodging | $352,625 | 1,055 | 3.3% |
| Food and Beverage | $112,717 | 1,516 | 1.0% |
| Consulting Fee | $13,170 | 2 | 0.1% |
| Education | $22.74 | 3 | 0.0% |
Payments by Type
Research
$8.9M
1,426 transactions
General
$1.9M
3,188 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Pharmacokinetic Properties of ARV and Related Drugs during Pregnancy and Postpartum (IMPAACT P1026s) | Gilead Sciences, Inc. | $1.6M | 0 |
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naive Adults | Gilead Sciences Inc | $1.0M | 0 |
| Effects of tenofovir alafenamide fumarate on coronary flow reverse in HIV stable HIV patients (TAF-CFR) | Gilead Sciences, Inc. | $1.0M | 0 |
| Real-world clinical outcomes of patients switched from complex multi-tablet regimens to TAF-based Single-Tablet Regimens plus a boosted Protease Inhibitor | Gilead Sciences, Inc. | $899,194 | 0 |
| Primary Infection Resource Consortium (PIRC) and Early Test Bundle (AEHIV 30/41) | Gilead Sciences, Inc. | $636,500 | 0 |
| A Phase 3b Randomized Open-Label Study to Evaluate the Benefit of Switching from Regimens Consisting of abacavir/lamivudine (ABC/3TC) plus a third agent to the Elvitegravir /Cobicistat /Emtricitabine /Tenofovir alafenamide (E/C/F/TAF) Single-Tablet Regimen in Virologically-Suppressed HIV-1 Infected Adult Patients | Gilead Sciences Inc | $390,272 | 0 |
| Bioequivalence of Crushed and Whole Genvoya Tablets (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate) | Gilead Sciences, Inc. | $371,096 | 0 |
| The Primary Infection Resource Consortium Network and Early Test Bundle: HIV NAT Screening, STI Testing & I-PrEP in At-Risk Individuals (AEHIV 042/AEHIV 041) | Gilead Sciences, Inc. | $362,784 | 0 |
| Feasibility Acceptance and Scalability of Empiric Treatment for Suspected Acutely HIV Infected Individuals in the Emergency Department | Gilead Sciences, Inc. | $300,000 | 0 |
| A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofavir Alafenamide Single Tablet Regimen in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Surpressed Children | Gilead Sciences, Inc. | $282,122 | 0 |
| Incidence of Hepatic Steatosis and Fibrosis in HIV patients, a cross-sectional study | Gilead Sciences, Inc. | $278,992 | 0 |
| A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in HIV-1 Infected Adults on Chronic Hemodialysis | Gilead Sciences, Inc. | $245,392 | 0 |
| Understanding Patient and Provider Perspectives on Rapid Antiretroviral Therapy Initiation | Gilead Sciences, Inc. | $244,682 | 0 |
| A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in HIV-1 Infected Adults on Chronic Hemodialysis | Gilead Sciences Inc | $210,188 | 0 |
| EFFECTS OF BICTEGRAVIR-EMTRICITABINE-TENOFOVIR ALAFENAMIDE ON CORONARY FLOW RESERVE IN STABLE HIV PATIENTS (B/F/TAF-CFR) - PILOT STUDY | Gilead Sciences, Inc. | $170,000 | 0 |
| A Phase 3, Open Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically Suppressed, HIV 1 Positive Subjects | Gilead Sciences Inc | $157,528 | 0 |
| A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofavir Alafenamide Single Tablet Regimen in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Surpressed Children | Gilead Sciences Inc | $114,406 | 0 |
| A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Patients with Mild to Moderate Renal Impairment | Gilead Sciences Inc | $102,234 | 0 |
| A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide (E/C/F/TAF) Fixed Dose Combination in Virologically-Suppressed HIV-1 Infected Adult Subjects Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I | Gilead Sciences, Inc. | $67,825 | 0 |
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naive Adults | Gilead Sciences, Inc. | $67,566 | 0 |
Top Doctors Receiving Payments for Genvoya
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| David Velez | — | Chicago, IL | $8.9M | 1,426 |
| , MD | Infectious Disease | Flushing, NY | $91,704 | 93 |
| , MD | Infectious Disease | Chicago, IL | $54,748 | 61 |
| , MD, MPH | Internal Medicine | San Francisco, CA | $42,667 | 60 |
| , M.D | Gastroenterology | Washington, DC | $41,078 | 46 |
| , MD | Infectious Disease | Briarcliff, NY | $39,694 | 36 |
| , MD | Internal Medicine | Fort Lauderdale, FL | $34,037 | 57 |
| , M.D | Infectious Disease | S Weymouth, MA | $32,751 | 39 |
| , MD | Infectious Disease | Bronx, NY | $29,972 | 37 |
| , M.D | Infectious Disease | Los Angeles, CA | $29,308 | 25 |
| , D.O | Geriatric Medicine | Phoenix, AZ | $25,220 | 40 |
| , MD | Infectious Disease | Chattanooga, TN | $23,996 | 30 |
| , MD, PHD | Infectious Disease | Seattle, WA | $22,458 | 28 |
| , MD | Infectious Disease | Harrisburg, PA | $18,276 | 22 |
| , DO FACOI | Infectious Disease | Somers Point, NJ | $17,244 | 23 |
| , MD | Internal Medicine | Charlotte, NC | $16,662 | 26 |
| , MD | Internal Medicine | New York, NY | $16,014 | 23 |
| , MD | Infectious Disease | Springfield, MA | $15,595 | 20 |
| , MD | Internal Medicine | Chicago, IL | $15,505 | 25 |
| , MD | Infectious Disease | Neptune, NJ | $15,457 | 21 |
| , MD | Adult Medicine | Washington, DC | $15,251 | 15 |
| , D.O | Infectious Disease | Denver, CO | $15,200 | 23 |
| , MD | Infectious Disease | Philadelphia, PA | $15,042 | 18 |
| , M.D | Infectious Disease | Miami Beach, FL | $14,747 | 24 |
| , M.D | Internal Medicine | Oakland, CA | $13,277 | 15 |
Ad
Manufacturing Companies
- Gilead Sciences, Inc. $6.8M
- Gilead Sciences Inc $4.0M
Product Information
- Type Drug
- Total Payments $10.8M
- Total Doctors 675
- Transactions 4,614
About Genvoya
Genvoya is a drug associated with $10.8M in payments to 675 healthcare providers, recorded across 4,614 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences Inc.
Payment data is available from 2017 to 2023. In 2023, $264,034 was paid across 6 transactions to 0 doctors.
The most common payment nature for Genvoya is "Unspecified" ($8.9M, 82.6% of total).
Genvoya is associated with 20 research studies, including "Pharmacokinetic Properties of ARV and Related Drugs during Pregnancy and Postpartum (IMPAACT P1026s)" ($1.6M).